Hepatic Angiomyolipoma Presenting as a Hyperintense Lesion During the Hepatobiliary Phase of Gadoxetic Acid Enhanced-MRI: a Case Report
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Gadoxetic acid-enhanced magnetic resonance imaging (MRI) has been widely used to detect and characterize focal hepatic lesions. Because gadoxetic acid is a hepatocytespecific contrast agent, its patterns during hepatobiliary phase enhancement provide useful information for differential diagnoses of focal hepatic lesions. Hepatic angiomyolipoma (AML) is a rare mesenchymal hepatic neoplasm composed of blood vessels, epithelioid cells, and varying amounts of adipose tissue components. Hepatic AMLs usually show marked hypointensity during the hepatobiliary phase of gadoxetic acid-enhanced MRI as hepatic AMLs are devoid of hepatocytes and fibrotic components. The present study describes a patient with hepatic AML and an atypical imaging feature. This tumor showed hyperintensity during the hepatobiliary phase of gadoxetic acid-enhanced MRI, mimicking hepatocellular tumors such as hepatocellular adenoma. The hepatobiliary hyperintensity of this lesion was likely due to multifocal entrapped hepatocytes resulting from an intrasinusoidal growth pattern of tumor cells and insufficient hepatic parenchymal enhancement during the hepatobiliary phase of gadoxetic acid-enhanced MRI.
Abstract
Gadoxetic acid-enhanced magnetic resonance imaging (MRI) has been widely used to detect and characterize focal hepatic lesions. Because gadoxetic acid is a hepatocytespecific contrast agent, its patterns during hepatobiliary phase enhancement provide useful information for differential diagnoses of focal hepatic lesions. Hepatic angiomyolipoma (AML) is a rare mesenchymal hepatic neoplasm composed of blood vessels, epithelioid cells, and varying amounts of adipose tissue components. Hepatic AMLs usually show marked hypointensity during the hepatobiliary phase of gadoxetic acid-enhanced MRI as hepatic AMLs are devoid of hepatocytes and fibrotic components. The present study describes a patient with hepatic AML and an atypical imaging feature. This tumor showed hyperintensity during the hepatobiliary phase of gadoxetic acid-enhanced MRI, mimicking hepatocellular tumors such as hepatocellular adenoma. The hepatobiliary hyperintensity of this lesion was likely due to multifocal entrapped hepatocytes resulting from an intrasinusoidal growth pattern of tumor cells and insufficient hepatic parenchymal enhancement during the hepatobiliary phase of gadoxetic acid-enhanced MRI.
참고문헌 (10)
- Joo I, "Recent advances in the imaging diagnosis of hepatocellular carcinoma : value of gadoxetic acidenhanced MRI", Liver Cancer, 5, pp.67~87 (2016)
- Fujita N, "Hyperintense liver masses at hepatobiliary phase gadoxetic acid-enhanced MRI : imaging appearances and clinical importance", Radiographics, 40, pp.72~94 (2020)
- Hui CL, "Patterns of enhancement in the hepatobiliary phase of gadoxetic acid-enhanced MRI", Br J Radiol, 93, pp.20190989~ (2020)
- World Health Organization Classification of Tumours Editorial Board, "Digestive system tumours", pp.485~487 (2019), World Health Organization
- Lee SJ, "Hepatic angiomyolipoma versus hepatocellular carcinoma in the noncirrhotic liver on gadoxetic acid-enhanced MRI : a diagnostic challenge", AJR Am J Roentgenol, 207, pp.562~570 (2016)
- Kim R, "Differentiation of lipid poor angiomyolipoma from hepatocellular carcinoma on gadoxetic acid-enhanced liver MR imaging", Abdom Imaging, 40, pp.531~541 (2015)
- Nonomura A, "Invasive growth of hepatic angiomyolipoma; a hitherto unreported ominous histological feature", Histopathology, 48, pp.831~835 (2006)
- Zhao C, "Hepatic epithelioid angiomyolipoma with prominent invasive growth pattern : a hitherto unreported histopathologic feature which might promote misdiagnosis", Clin Diagn Pathol, 2, pp.1~4 (2018)
- Yoon JH, "Quantitative assessment of liver function by using gadoxetic acid-enhanced MRI : hepatocyte uptake ratio", Radiology, 290, pp.125~133 (2019)
- Unal E, "Hyperintensity at fat spared area in steatotic liver on the hepatobiliary phase MRI", Diagn Interv Radiol, 25, pp.416~420 (2019)